Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC

Background: A significant proportion of patients with non-small-cell lung cancer (NSCLC) do not respond to immune checkpoint inhibitors (ICIs). Since metabolic reprogramming with increased glycolysis is a hallmark of cancer and is involved in immune evasion, we used 18F-fluorodeoxyglucose positron e...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Therapeutic advances in medical oncology 2022-01, Vol.14, p.17588359221138386-17588359221138386
Hauptverfasser:	Silva, Saulo Brito, Wanderley, Carlos Wagner S., Gomes Marin, José Flavio, Macedo, Mariana Petaccia de, do Nascimento, Ellen Caroline Toledo, Antonacio, Fernanda Frozoni, Figueiredo, Caroline Sales, Trinconi Cunha, Mateus, Cunha, Fernando Q., Castro Junior, Gilberto de
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis Cell death Chemotherapy Computed tomography Glucose transporter Glycolysis Immune checkpoint inhibitors Immunohistochemistry Lung cancer Metabolism Non-small cell lung carcinoma Original Research PD-L1 protein Positron emission tomography Small cell lung carcinoma Tomography Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!